Public preview. Funding rounds, founders, and growth signals require a free account.

Ajax Therapeutics, Inc.

Develops next-generation Type II JAK2 inhibitors for myeloproliferative neoplasms (MPNs) like myelofibrosis.

GrowthBiotechNew York, NY

Total raised

$140.4M

Last round

Equity

$95.0M · Apr 2024

Stage

Growth

Status

Active

Founders & team

Co-founder, CEO

Co-founder, CTO

Head of Engineering

Head of Sales

🔒

Free account unlocks founder names, LinkedIn profiles, and prior companies.

Web traffic

Search interest

Social followers

Glassdoor rating

News mentions

Gov contracts

🔒

Free account unlocks 5 full profiles per day. Pro removes the limit.

Get notified the moment Ajax Therapeutics, Inc. files a new round, hires execs, or shows traction signals.

About this data

FlareSight surfaces funding data from SEC Form D filings within hours of submission. Browse our full startup funding database to find more recently funded companies.